Moderna dropped 'vaccine' from its mRNA cancer shot branding in 2023, rebranding it 'individualized neoantigen therapy' to avoid political stigma.
Moderna and Merck's mRNA cancer shot halved recurrence deaths in the deadliest skin cancer, but Moderna stopped calling it a 'vaccine' in regulatory filings after 2023, rebranding it 'individualized neoantigen therapy' (INT). BioNTech made a similar linguistic shift. Moderna's CEO framed it as clarifying the program's goals, but the company's own cancer program head acknowledged vaccines are now a 'dirty word.' A physician running the trials raised ethics concerns about whether patients are being fully informed when consenting.
This story has zero direct implications for AI or software developers. The underlying mRNA mechanism hasn't changed; only the regulatory and marketing language has. If you're building in digital health or clinical trial tooling, the informed consent documentation angle is the only technical touchpoint — systems may need to reflect updated product nomenclature.
If you build clinical trial or EHR software, audit whether your data schemas use 'vaccine' vs. 'therapy' classifications for Moderna's INT — a mismatch now creates compliance risk as regulatory filings diverge from legacy trial language.
Suggested exercise · not independently tested. Access requirements and costs may vary.
Go to perplexity.ai
Search: 'Moderna individualized neoantigen therapy IND filing terminology change FDA 2023 2024'
Scan the regulatory filing summaries and trial registration records for how the product is classified
Tags
Sources